{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-003645","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.643445+00:00","generated_at":"2026-05-26T23:58:07.895344+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Grace Therapeutics: Phase 3 STRIVE-ON trial meets endpoint; announces up to $30M private placement","bullets":["Phase 3 STRIVE-ON safety trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; NDA submission expected H1 2025.","Private placement of up to ~$30M gross proceeds ($15M upfront + up to $15M from warrant exercise); led by Nantahala Capital and ADAR1 Partners.","Net proceeds ~$13.8M after fees; expected close Feb 11, 2025; funds for general corporate purposes and GTx-104 pre-commercial development.","54% of GTx-104 patients achieved ≥95% relative dose intensity vs 8% on oral nimodipine; favorable functional outcomes and fewer ICU days observed.","Common warrants exercisable at $3.395/share; expire on earlier of 60 days post-FDA approval or Sep 25, 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-003645","json":"https://secwatch.observer/filing/0001140361-25-003645.json","markdown":"https://secwatch.observer/filing/0001140361-25-003645.md","text":"https://secwatch.observer/filing/0001140361-25-003645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125003645/0001140361-25-003645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125003645/ef20043150_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:58:07.895344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}